There were 574 press releases posted in the last 24 hours and 158,437 in the last 365 days.

Generex Presents Encouraging Interim Results Of Phase II Breast Cancer Study

December 16, 2009 (FinancialWire) — Generex Biotechnology Corp. (NASDAQ: GNBT) announced presentation of interim results from a Phase II efficacy study of a novel immunotherapeutic vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc.

The results were presented at the 32nd Annual San Antonio Breast Cancer Symposium (www.sabcs.org). The trial is being conducted by COL George Peoples, MD, a collaborator of Antigen Express working at the Brooke Army Medical Center.

The presentation, entitled Interim analysis of a randomized phase II study of the novel Ii-Key hybrid HER2/neu peptide vaccine to prevent breast cancer recurrence: United States Military Cancer Institute Clinical Trials Group Study I-05, showed that at a median follow-up of 13 months, there were no relapses in patients receiving the AE37 immunotherapeutic vaccine for breast cancer (0 of 49 patients) while relapses were observed in the control group (5 of 71 patients). The trial is a fully randomized and controlled study examining the rate of relapse in patients diagnosed with node-positive or high risk node negative breast cancer. The final endpoint will examine the relapse rate after two years; the results presented at the conference were those observed in patients 13.5 months after treatment.

Antigen Express, Generex’s immunotherapy division, is developing novel synthetic peptide vaccines for potent and specific stimulation of CD4+ T helper cells. The vaccine being studied in this trial, AE37, was shown to be safe, well-tolerated and produced the desired immunological activity in both a Phase I trial in breast cancer patients and a Phase I trial in patients with prostate cancer. AE37 is also the subject of an additional Phase I clinical trial in patients with breast or ovarian cancer in which it is being combined with another immunotherapeutic peptide.

In addition to cancer, the proprietary Antigen Express technology is being applied to vaccine development for infectious diseases. In particular, a synthetic peptide vaccine is currently being developed for the H1N1 swine flu virus.

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.